| Nov 12 |
Nkarta to Participate in an Upcoming Investor Conference
|
| Nov 8 |
Nkarta ending development of asset for lymphoma
|
| Nov 7 |
Nkarta GAAP EPS of -$0.39 misses by $0.03
|
| Nov 7 |
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
|
| Oct 31 |
Nkarta (NKTX) Stock: Looking For Upside
|
| Oct 31 |
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
|
| Oct 18 |
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
|
| Oct 9 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
|
| Sep 3 |
Nkarta to Participate in Upcoming Investor Conference
|
| Aug 14 |
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
|
